scholarly journals Radium‑223 in patients with metastatic castration‑resistant prostate cancer: Efficacy and safety in clinical practice

2018 ◽  
Author(s):  
Arsela Prelaj ◽  
Sara Rebuzzi ◽  
Federica Buzzacchino ◽  
Chiara Pozzi ◽  
Carla Ferrara ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Clinical Practice ◽  
Efficacy And Safety ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant ◽  
Radium 223

scholarly journals Radium-223 in metastatic castration-resistant prostate cancer (mCRPC): efficacy and safety in real-life experience

2017 ◽  
Vol 28 ◽  
pp. vi23-vi24
Author(s):  
S.E. Rebuzzi ◽  
A. Prelaj ◽  
C. Pozzi ◽  
C. Ferrara ◽  
V. Frantellizzi ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Life Experience ◽  
Real Life ◽  
Efficacy And Safety ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant ◽  
Radium 223

scholarly journals Radium-223 for the treatment of patients with castration-resistant prostate cancer with bone metastases

2018 ◽  
pp. 78-82
Author(s):  
A. D. Kaprin ◽  
A. A. Kostin ◽  
N. V. Vorobyev ◽  
S. V. Popov
Keyword(s):  
Prostate Cancer ◽  
Bone Metastases ◽  
Efficacy And Safety ◽  
Castration Resistant Prostate Cancer ◽  
Good Tolerability ◽  
Development Of Resistance ◽  
Castration Resistant ◽  
Radium 223 ◽  
Visceral Metastases ◽  
Bone Complications

The development of resistance to endocrine therapy and the tumor progression in patients with prostate cancer are associated with an unfavourable prognosis. The article presents a review of clinical trials of efficacy and safety, as well as the experience in using radioisotope radium-223 chloride in clinical practice in patients with castration-resistant prostate cancer with bone metastases without visceral metastases. It was shown that radium-223 chloride therapy in this category of patients leads to an increase in overall survival and time to the development of bone complications, and is characterized by good tolerability.

Integration of radium-223 dichloride (Xofigo) into clinical practice for the treatment of castration-resistant prostate cancer.

2019 ◽  
Vol 37 (7_suppl) ◽  
pp. 312-312
Author(s):  
Catherine Mary Doyle ◽  
Matthew Mills ◽  
Sultan Damgaci ◽  
Johnna Smith ◽  
Jingsong Zhang ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Clinical Practice ◽  
Bone Metastases ◽  
Univariate Analysis ◽  
Treatment Completion ◽  
Categorical Variables ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant ◽  
Radium 223 ◽  
Complete Treatment

312 Background: Radium-223 dichloride (Xofigo) is an FDA-approved radionuclide used to treat symptomatic bone metastases in patients with castration-resistant prostate cancer (CRPC) with no known visceral metastases. Outside of clinical trial, the benefits of Radium-223 dichloride (Ra-223) in the treatment of CRPC have not yet been fully delineated in real life setting. Therefore, the purpose of this study was to evaluate the outcome of patients with CRPC who were treated with Ra-223, especially studying the variables associated with completion of 6 cycles of therapy. Methods: A total of 114 patients with CRPC and bone metastases referred for treatment with Ra-223 between March 2010 and February 2018 were identified for retrospective analysis. A chart review was conducted to analyze clinical characteristics, treatments, and outcomes including radiologic bone scans. Categorical variables were compared using Chi-square and independent student t test, and survival rates were generated using Kaplan-Meier analysis. Multivariate analysis (MVA) Cox proportional hazard ratios (HR) model was used in the assessment of OS and PFS. Results: Of the 114 patients referred for treatment, the overall median OS was 12.6 months. In MVA, improved OS was most strongly associated with completion of all six doses (p < 0.001). Median OS for the 56 patients who received full treatment was 24 months, while median OS for the 107 patients who did not complete treatment was 5.9 months. In univariate analysis, treatment completion was significantly associated with prior Sipuleucel-T (p = 0.002), concurrent Denosumab (p = 0.027), and baseline PSA < 30 ng/mL (p = 0.004). Conclusions: Completion of treatment with Ra-223 is a significant factor associated with improved OS. Therefore it is clinically important to delineate which patients are to the most appropriate candidates to complete treatment. Factors notable for treatment completion suggest patients might benefit from initiating Ra-223 treatment after receiving Sipuleucel-T and while their PSA remains low. Further consideration should be given to the sequence of Ra-223 in clinical practice, including use of concurrent Abiraterone and Enzalutamide.

Outcomes with Radium-223 therapy in clinical practice of metastatic castration resistant prostate cancer (mCRPC).

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. e16073-e16073
Author(s):  
Ajjai Shivaram Alva ◽  
Luke T. Nordquist ◽  
Stephanie Daignault ◽  
Saby George ◽  
Jorge Ramos ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Clinical Practice ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant ◽  
Radium 223
Sign in / Sign up

Export Citation Format

Share Document